Feline Injection-Site Sarcoma: Welfare and Treatment

Injection-site sarcoma is a rare but aggressive cancer occurring at vaccination sites in cats, requiring radical surgery and carrying a guarded prognosis.

Key Facts

Injection-site sarcomas (FISS) occur at a rate of approximately 1-4 per 10,000 vaccines administered — rare but serious
They are typically high-grade fibrosarcomas that grow rapidly and have a high local recurrence rate after incomplete excision
Vaccination protocols have been modified — vaccines are now given in the distal limb where amputation offers a curative option if sarcoma develops
The Vaccine-Associated Sarcoma Task Force recommends the 3-2-1 rule for biopsy referral: any mass persisting at a vaccination site 3 months post-vaccination, larger than 2cm or growing after 1 month

Welfare Considerations

FISS welfare management requires balancing the significant benefit of vaccination against the small risk of sarcoma development. Aggressive early surgery — with wide margins of 3-5cm and full fascial planes — is the most important welfare intervention when sarcoma is confirmed, as local recurrence from inadequate margins is the most common treatment failure. Adjuvant chemotherapy and radiation therapy improve local control but do not cure metastatic disease. Owners benefit from clear discussion about treatment options, prognosis and quality of life throughout treatment planning.

What You Can Do

Administer vaccines in distal limb sites per current guidelines — this enables amputation as a treatment option if sarcoma develops
Apply the 3-2-1 rule and refer any concerning vaccination site mass to an oncologist for biopsy
Do not attempt excision without pre-surgical staging — chest radiographs and CT planning improve surgical outcomes
Discuss quality of life honestly throughout treatment — FISS carries a guarded prognosis even with aggressive management